Rocaglamide Liposomes, Formulation KHE9A
3327.95 €
In Stock
quantity
product details
Catalog number: 1142 - DLL-0019-1A-25MG
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 25 mg
DLL-0019-1A-10MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
2014.95 €
DLL-0019-1A-25MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3327.95 €
DLL-0019-1A-5MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1307.95 €
FL-0001-10ML
DiR Labeled Tumor-Accumulating Liposomes™
Long-circulating, tumor-accumulating fluorescent liposomes (DiR-labeled). These fluorescent liposomes passively accumulate in solid tumor tissues for a variety of murine tumor models and are labeled with the fluorescent dye, DiR, making them excellent for in vivo and ex vivo imaging studies in rodents. The liposomes are compatible for use with PerkinElmer In Vivo Imaging Systems (IVIS) equipped with DiR filter set (DiR Absorption/Emission: 748/780; IVIS Filter Set: 710 ex/760 em [1]). PEGylated to improve stability, prolong circulation time and reduce reticuloendothelial system clearance for in vivo applications. The lipid composition is very similar to that of the well-characterized Doxil® formulation.
1913.95 €
FL-0001-2ML
DiR Labeled Tumor-Accumulating Liposomes™
Long-circulating, tumor-accumulating fluorescent liposomes (DiR-labeled). These fluorescent liposomes passively accumulate in solid tumor tissues for a variety of murine tumor models and are labeled with the fluorescent dye, DiR, making them excellent for in vivo and ex vivo imaging studies in rodents. The liposomes are compatible for use with PerkinElmer In Vivo Imaging Systems (IVIS) equipped with DiR filter set (DiR Absorption/Emission: 748/780; IVIS Filter Set: 710 ex/760 em [1]). PEGylated to improve stability, prolong circulation time and reduce reticuloendothelial system clearance for in vivo applications. The lipid composition is very similar to that of the well-characterized Doxil® formulation.
701.95 €